COMPANY

Metabolic Solutions Development Company, LLC

HQ: Kalamazoo, MI source · msdrx.com ↗ · Midwest

Keywords: metabolic type 2 diabetes mellitus non-alcoholic fatty liver disease Alzheimer's Disease polycystic kidney disease MSDC-0602 MSDC-0160

Location: Kalamazoo, MI · source · Feb 6, 2019

Profile checked Oct 10, 2026

4Trials (company is sponsor)8NIH grants

Timeline

2011-07 Trial start Phase 2: 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease source ↗
2011-02 Trial start Phase 2: A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Pati source ↗
2010-09 Trial start Phase 2: Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients source ↗
2008-09 Trial start Phase 2: A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT01103414	Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients	Phase 2	Completed	2010-09	2011-11 (actual)
NCT01374438	3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease	Phase 2	Completed	2011-07	2013-03 (actual)
NCT01280695	A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients	Phase 2	Completed	2011-02	2011-06 (actual)
NCT00760578	A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator	Phase 2	Completed	2008-09	2009-01 (actual)

NIH awards 8

Annual award amounts. Total $2.8M.

Sep 23, 2014 NIH award 1R43DK104508-01 FY2014: $121,956 awarded for that fiscal year; activity R43 (SBIR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. Therapeutic Use of mTOT Modu source ↗
Sep 11, 2012 NIH award 3R42AA021228-03S1 FY2012: $50,000 awarded for that fiscal year; activity R42 (STTR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. Evaluation of PPARgam-spari source ↗
Aug 16, 2012 NIH award 5R42AA021228-03 FY2012: $560,998 awarded for that fiscal year; activity R42 (STTR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. Evaluation of PPARgam-sparin source ↗
Sep 15, 2011 NIH award 9R42AA021228-02A1 FY2011: $563,804 awarded for that fiscal year; activity R42 (STTR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. Evaluation of PPARgam-spar source ↗
Mar 25, 2011 NIH award 5R42DK081298-03 FY2011: $634,311 awarded for that fiscal year; activity R42 (STTR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. PPAR-sparing/free Thiazolidi source ↗
Mar 31, 2010 NIH award 4R42DK081298-02 FY2010: $608,312 awarded for that fiscal year; activity R42 (STTR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. PPAR-sparing/free Thiazolidi source ↗
Aug 31, 2009 NIH award 1R41DK084596-01 FY2009: $140,911 awarded for that fiscal year; activity R41 (STTR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. Evaluation of PPARgam-sparin source ↗
Apr 27, 2009 NIH award 1R42DK081298-01A1 FY2009: $139,864 awarded for that fiscal year; activity R42 (STTR); PI KLETZIEN, ROLF F; recipient as written: METABOLIC SOLUTIONS DEVELOPMENT CO, KALAMAZOO, MI. PPAR-sparing/free Thiazoli source ↗